Articles

BHS guidelines on supportive care in lymphoma: Part 2

BJH - volume 13, issue 4, june 2022

M. Janssens MD, K. Saevels MD, V. Vergote MD, J. Lemmens MD, S. Bailly MD, A. Janssens MD, PhD, S. Snauwaert MD, PhD, M. André MD, PhD

SUMMARY

Besides disease-directed therapy, patients with lymphoma are in need of a wide range of supportive measures. In the second part of this guideline, the prevention and treatment of tumour lysis syndrome, cardiac support and physiotherapy are discussed.

(BELG J HEMATOL 2022;13(4):149–55)

Read more

BHS guidelines on supportive care in lymphoma: Part 1

BJH - volume 13, issue 3, may 2022

M. Janssens MD, K. Saevels MD, V. Vergote MD, J. Lemmens MD, S. Bailly MD, A. Janssens MD, PhD, S. Snauwaert MD, PhD, M. André MD, PhD

SUMMARY

Besides disease-directed therapy, patients with lymphoma are in need of a wide range of supportive measures. In the first part of this guideline the use of anti-emetic therapy, the use of granulocyte colony stimulating factor (G-CSF) and antibiotic prophylaxis for pneumocystis jirovecii are discussed. In part 2 of this guideline we will discuss cardiac support, prevention and treatment of tumour lysis syndrome and the role of physiotherapy.

(BELG J HEMATOL 2022;13(3):116–23)

Read more

P.24 Rare morphologic phenomena in plasma cell dyscrasia: report of two cases

BJH - volume 11, issue Abstract Book BHS, february 2020

K. Kehoe , S. Weekx , S. Vermeiren , K. Ver Elst , T. Eyckmans MD, C. Schuermans MD, J. Lemmens MD

Read more

Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases

BJH - volume 10, issue 2, march 2019

S. Snauwaert MD, PhD, J. Lemmens MD, A. Janssens MD, PhD, T. Kerre MD, PhD

High-dose chemotherapy and autologous or allogeneic haematopoietic stem cell transplantation are widely used in the treatment of lymphoproliferative diseases. For chemo-sensitive relapsed lymphoma (Hodgkin’s and non-Hodgkin’s lymphoma) high-dose chemotherapy and autologous stem cell transplantation are generally accepted as a standard treatment. Emerging data exist for the use of haematopoietic stem cell transplantation in other disease stages for mantle cell lymphoma, follicular lymphoma and some T-cell lymphomas. The use of haematopoietic stem cell transplantation in other conditions is more controversial and remains a clinical option for selected patients or experimental within the framework of a clinical trial.

(BELG J HEMATOL 2019;10(2):69–79)

Read more

P2.09 Prekallikrein deficiency in a 15-year-old boy with Ménière’s disease: a case report

BJH - volume 7, issue Abstract Book BHS, january 2016

M. Criel , F. Declau , C. Schuermans MD, K. Ver Elst , S. Vermeiren , S. Weekx , J. Lemmens MD

Read more